Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1NET 1Genitourinary 1Endocrine 1Breast 1

Conditions

Prostatic Neoplasms 594Carcinoma, Renal Cell 276Urinary Bladder Neoplasms 175Kidney Neoplasms 112Neoplasms 101Neoplasm Metastasis 94Carcinoma, Non-Small-Cell Lung 94Carcinoma, Transitional Cell 86Melanoma 85Breast Neoplasms 83Ovarian Neoplasms 64Lung Neoplasms 50Colorectal Neoplasms 50Pancreatic Neoplasms 43Stomach Neoplasms 40Sarcoma 37Squamous Cell Carcinoma of Head and Neck 35Triple Negative Breast Neoplasms 31Testicular Neoplasms 29Uterine Cervical Neoplasms 27Esophageal Neoplasms 26Carcinoma, Hepatocellular 26Head and Neck Neoplasms 24Non-Muscle Invasive Bladder Neoplasms 23Small Cell Lung Carcinoma 22Colonic Neoplasms 20Urologic Neoplasms 17Neuroblastoma 17Multiple Myeloma 17Endometrial Neoplasms 17

Interventions

cabazitaxel 1XRP6258 1Prednisone 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Diarrhea × Genitourinary × Clear all
NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

University of Southern California

Phase 2 Terminated
9 enrolled
Genitourinary

Diarrhea, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡